Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

References for PMC Articles for PubMed (Select 23153828)

1.

C3-dependent mechanism of microglial priming relevant to multiple sclerosis.

Ramaglia V, Hughes TR, Donev RM, Ruseva MM, Wu X, Huitinga I, Baas F, Neal JW, Morgan BP.

Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):965-70. doi: 10.1073/pnas.1111924109. Epub 2012 Jan 4.

2.

Complement receptor 1 (CR1) and Alzheimer's disease.

Crehan H, Holton P, Wray S, Pocock J, Guerreiro R, Hardy J.

Immunobiology. 2012 Feb;217(2):244-50. doi: 10.1016/j.imbio.2011.07.017. Epub 2011 Jul 23. Review.

PMID:
21840620
3.

The three new pathways leading to Alzheimer's disease.

Morgan K.

Neuropathol Appl Neurobiol. 2011 Jun;37(4):353-7. doi: 10.1111/j.1365-2990.2011.01181.x.

PMID:
21486313
4.

Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites.

Brouwers N, Van Cauwenberghe C, Engelborghs S, Lambert JC, Bettens K, Le Bastard N, Pasquier F, Montoya AG, Peeters K, Mattheijssens M, Vandenberghe R, Deyn PP, Cruts M, Amouyel P, Sleegers K, Van Broeckhoven C.

Mol Psychiatry. 2012 Feb;17(2):223-33. doi: 10.1038/mp.2011.24. Epub 2011 Mar 15.

5.

Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease.

Hu X, Pickering E, Liu YC, Hall S, Fournier H, Katz E, Dechairo B, John S, Van Eerdewegh P, Soares H; Alzheimer's Disease Neuroimaging Initiative.

PLoS One. 2011 Feb 24;6(2):e16616. doi: 10.1371/journal.pone.0016616.

6.

Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.

Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Güntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S.

Arch Gen Psychiatry. 2010 Jul;67(7):739-48. doi: 10.1001/archgenpsychiatry.2010.78.

7.

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.

Brunden KR, Trojanowski JQ, Lee VM.

Nat Rev Drug Discov. 2009 Oct;8(10):783-93. doi: 10.1038/nrd2959. Review.

8.

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.

Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O; European Alzheimer's Disease Initiative Investigators, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alpérovitch A, Lathrop M, Amouyel P.

Nat Genet. 2009 Oct;41(10):1094-9. doi: 10.1038/ng.439. Epub 2009 Sep 6.

PMID:
19734903
9.

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, Heun R, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J.

Nat Genet. 2009 Oct;41(10):1088-93. doi: 10.1038/ng.440. Epub 2009 Sep 6. Erratum in: Nat Genet. 2009 Oct;41(10):1156. Nat Genet. 2013 Jun;45(6):712. Haun, Reinhard [added].

10.

Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice.

Killick R, Scales G, Leroy K, Causevic M, Hooper C, Irvine EE, Choudhury AI, Drinkwater L, Kerr F, Al-Qassab H, Stephenson J, Yilmaz Z, Giese KP, Brion JP, Withers DJ, Lovestone S.

Biochem Biophys Res Commun. 2009 Aug 14;386(1):257-62. doi: 10.1016/j.bbrc.2009.06.032. Epub 2009 Jun 10.

11.

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal.

Hardy J.

J Neurochem. 2009 Aug;110(4):1129-34. doi: 10.1111/j.1471-4159.2009.06181.x. Epub 2009 May 18. Review.

PMID:
19457065
12.

Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease.

Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A, Simmons A, Murphy D, Lovestone S.

J Neurol. 2008 Nov;255(11):1712-20. doi: 10.1007/s00415-008-0006-8. Epub 2008 Aug 1.

PMID:
19156487
13.

Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury.

Ruseva MM, Hughes TR, Donev RM, Sivasankar B, Pickering MC, Wu X, Harris CL, Morgan BP.

Mol Immunol. 2009 Feb;46(5):803-11. doi: 10.1016/j.molimm.2008.09.003. Epub 2008 Oct 22.

PMID:
18947875
14.

Proteome-based plasma biomarkers for Alzheimer's disease.

Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S.

Brain. 2006 Nov;129(Pt 11):3042-50.

15.

Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro.

Necula M, Kuret J.

J Biol Chem. 2004 Nov 26;279(48):49694-703. Epub 2004 Sep 10.

16.

Promotion of hyperphosphorylation by frontotemporal dementia tau mutations.

Alonso Adel C, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K.

J Biol Chem. 2004 Aug 13;279(33):34873-81. Epub 2004 Jun 9.

18.

Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain.

Strohmeyer R, Ramirez M, Cole GJ, Mueller K, Rogers J.

J Neuroimmunol. 2002 Oct;131(1-2):135-46.

PMID:
12458045
19.

The role of complement in Alzheimer's disease pathology.

Emmerling MR, Watson MD, Raby CA, Spiegel K.

Biochim Biophys Acta. 2000 Jul 26;1502(1):158-71. Review.

20.

A critical role for murine complement regulator crry in fetomaternal tolerance.

Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H.

Science. 2000 Jan 21;287(5452):498-501.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk